Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation

Gustavo S Fernandes,Daniel M Girardi,Felipe P Fonseca,João Paulo G Bernardes,Eduardo R Fregnani

doi:10.1186/s12885-018-4802-y

Gustavo S Fernandes, Daniel M Girardi + Show 3 more

Open Access

https://doi.org/10.1186/s12885-018-4802-y

Copy DOI

Abstract

BackgroundAmeloblastoma is a slow-growing neoplasm of the jaw, for which the standard treatment is surgical removal of the lesion with high recurrence rates and elevated morbidity. Systemic therapy is not established in the literature.Case presentationWe present a case of a 29-year-old woman diagnosed with an ameloblastoma of the left mandible who had been subjected to several surgical procedures over twenty years due to multiple local recurrences. Molecular testing revealed a BRAF V600E mutation, and vemurafenib was started. She experienced complete resolution of symptoms related to the disease, and image scans evidenced continuous shrinkage of the neoplastic lesion after eleven months of therapy.ConclusionThis is the first report showing clinical benefit and radiological response with vemrafenib for recurrent ameloblastoma. Targeted therapy addressing BRAF V600E mutation has the potential to change clinical practice of this rare disease.

Highlights

Ameloblastoma is a slow-growing neoplasm of the jaw, for which the standard treatment is surgical removal of the lesion with high recurrence rates and elevated morbidity
Ameloblastoma is a locally invasive, slow-growing odontogenic neoplasm arising in the jaw, which accounts for 13–58% of odontogenic tumors [1]
Here we report a case of disease control with BRAF inhibitor monotherapy for recurrent ameloblastoma

Summary

Introduction

Ameloblastoma is a slow-growing neoplasm of the jaw, for which the standard treatment is surgical removal of the lesion with high recurrence rates and elevated morbidity. Conclusion: This is the first report showing clinical benefit and radiological response with vemrafenib for recurrent ameloblastoma. Targeted therapy addressing BRAF V600E mutation has the potential to change clinical practice of this rare disease. Elucidations of the molecular pathways that lead to development of the disease have revealed new treatment possibilities.

Results

Conclusion